Drug · FAERS side-effect profile with label screen

Sodium, Potassium and Sodium side effects: what 969 FDA adverse event reports show

Sodium Chloride, Potassium Chloride, Sodium Lactate And Calcium Chloride · 22 reaction terms · 273 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Label matched

Sodium Chloride, Potassium Chloride, Sodium Lactate And Calcium Chloride (Lactated Ringers)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

969 reports · 88% serious · 111 with death outcome · 62% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Lactated Ringer’s Injection is indicated for use as a source of water and electrolytes or as an alkalinizing agent in adults and pediatric patients. Lactated Ringer’s Injection is indicated for use as a source of water and electrolytes or as an alkalinizing agent in adults and pediatric patients. ( 1 )

FDA label, Indications and Usage

What it is

Lactated Ringer’s Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1 .

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 18 strongest signals

Labeled (related wording) 3Reporting / coding artifact 2Lab value / disease marker 1Not in label — unassessed 12

What the badges mean

Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 4 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Blindness	50	26.6 20.3–34.9ROR 28.0 · χ² 1,208 / p 7e-265	26.3 EB05 20.8 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious PRR 17.9 · ♀ 24% (drug 62%) · 100% clinician	no trial data cached
Caesarean section	14	25.8 15.3–43.4ROR 26.2 · χ² 309 / p 2e-69	24.9 EB05 15.7 · IC025 +2.9 3/3 methods agree	Not in label — unassessed	serious PRR 16.1	no trial data cached
Multi-organ failure	16	19.8 12.1–32.1ROR 20.1 · χ² 266 / p 4e-60	19.2 EB05 12.2 · IC025 +2.8 3/3 methods agree	Not in label — unassessed	serious PRR 13.0	no trial data cached
Ventricular tachycardia	13	17.0 9.9–29.2ROR 17.2 · χ² 180 / p 3e-41	16.1 EB05 9.2 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 11.2	no trial data cached
Fear	20	16.0 10.4–24.7ROR 16.3 · χ² 266 / p 4e-60	15.5 EB05 10.2 · IC025 +2.8 3/3 methods agree	Not in label — unassessed	serious PRR 14.2	no trial data cached
Drug exposure during pregnancy	22	13.8 9.1–20.9ROR 14.1 · χ² 249 / p 2e-56	13.2 EB05 8.8 · IC025 +2.7 3/3 methods agree	Reporting / coding artifact	serious PRR 8.2 · ♀ 95% (drug 62%)	no trial data cached
Eye inflammation	6	13.8 6.2–30.6ROR 13.9 · χ² 59 / p 9e-15	10.1 EB05 4.0 · IC025 +1.4 3/3 methods agree	Labeled (related wording) related wording	serious n=1	no trial data cached
Pruritus generalised	12	11.8 6.7–20.8ROR 12.0 · χ² 109 / p 1e-25	10.2 EB05 5.6 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 13.5	no trial data cached
Renal injury	16	11.5 7.1–18.8ROR 11.7 · χ² 144 / p 2e-33	10.3 EB05 6.2 · IC025 +2.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.6	no trial data cached
Anaphylactic shock	13	11.0 6.4–18.8ROR 11.1 · χ² 108 / p 1e-25	9.4 EB05 5.4 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 7.2	no trial data cached
Body temperature decreased	5	10.9 4.5–26.1ROR 11.0 · χ² 36 / p 1e-9	7.0 EB05 2.8 · IC025 +1.0 3/3 methods agree	Lab value / disease marker	serious PRR 3.2	no trial data cached
Disseminated intravascular coagulation	7	10.7 5.1–22.5ROR 10.8 · χ² 52 / p 2e-13	7.8 EB05 3.6 · IC025 +1.4 3/3 methods agree	Not in label — unassessed	serious PRR 7.1	no trial data cached
Infusion related reaction (reaction during infusion)	28	9.2 6.4–13.2ROR 9.4 · χ² 196 / p 6e-45	8.4 EB05 6.0 · IC025 +2.4 3/3 methods agree	Labeled (related wording) related wording	serious PRR 5.4	no trial data cached
Anhedonia	10	8.2 4.4–15.1ROR 8.2 · χ² 56 / p 4e-14	6.4 EB05 3.6 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious PRR 5.9	no trial data cached
Serotonin syndrome	6	6.8 3.1–15.1ROR 6.8 · χ² 24 / p 5e-7	4.8 EB05 2.3 · IC025 +0.8 3/3 methods agree	Not in label — unassessed	serious PRR 4.5	no trial data cached
Premature baby	9	6.5 3.4–12.4ROR 6.5 · χ² 36 / p 9e-10	5.0 EB05 2.8 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 4.3	no trial data cached
Drug administration error	6	4.2 1.9–9.3ROR 4.2 · χ² 11 / p 4e-4	3.3 EB05 1.7 · IC025 +0.3	Reporting / coding artifact	serious PRR 5.4	no trial data cached
Pharmaceutical product complaint	5	4.1 1.7–9.8ROR 4.1 · χ² 9 / p 0.001	3.2 EB05 1.5 · IC025 +0.1	Not in label — unassessed	serious PRR 0.9	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Blindness	50	26.6 20.3–34.9ROR 28.0 · χ² 1,208 / p 7e-265	26.3 EB05 20.8 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious PRR 17.9 · ♀ 24% (drug 62%) · 100% clinician	no trial data cached
Infusion related reaction (reaction during infusion)	28	9.2 6.4–13.2ROR 9.4 · χ² 196 / p 6e-45	8.4 EB05 6.0 · IC025 +2.4 3/3 methods agree	Labeled (related wording) related wording	serious PRR 5.4	no trial data cached
Drug exposure during pregnancy	22	13.8 9.1–20.9ROR 14.1 · χ² 249 / p 2e-56	13.2 EB05 8.8 · IC025 +2.7 3/3 methods agree	Reporting / coding artifact	serious PRR 8.2 · ♀ 95% (drug 62%)	no trial data cached
Fear	20	16.0 10.4–24.7ROR 16.3 · χ² 266 / p 4e-60	15.5 EB05 10.2 · IC025 +2.8 3/3 methods agree	Not in label — unassessed	serious PRR 14.2	no trial data cached
Renal injury	16	11.5 7.1–18.8ROR 11.7 · χ² 144 / p 2e-33	10.3 EB05 6.2 · IC025 +2.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.6	no trial data cached
Multi-organ failure	16	19.8 12.1–32.1ROR 20.1 · χ² 266 / p 4e-60	19.2 EB05 12.2 · IC025 +2.8 3/3 methods agree	Not in label — unassessed	serious PRR 13.0	no trial data cached
Caesarean section	14	25.8 15.3–43.4ROR 26.2 · χ² 309 / p 2e-69	24.9 EB05 15.7 · IC025 +2.9 3/3 methods agree	Not in label — unassessed	serious PRR 16.1	no trial data cached
Anaphylactic shock	13	11.0 6.4–18.8ROR 11.1 · χ² 108 / p 1e-25	9.4 EB05 5.4 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 7.2	no trial data cached
Ventricular tachycardia	13	17.0 9.9–29.2ROR 17.2 · χ² 180 / p 3e-41	16.1 EB05 9.2 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 11.2	no trial data cached
Pruritus generalised	12	11.8 6.7–20.8ROR 12.0 · χ² 109 / p 1e-25	10.2 EB05 5.6 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 13.5	no trial data cached
Anhedonia	10	8.2 4.4–15.1ROR 8.2 · χ² 56 / p 4e-14	6.4 EB05 3.6 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious PRR 5.9	no trial data cached
Premature baby	9	6.5 3.4–12.4ROR 6.5 · χ² 36 / p 9e-10	5.0 EB05 2.8 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 4.3	no trial data cached
Disseminated intravascular coagulation	7	10.7 5.1–22.5ROR 10.8 · χ² 52 / p 2e-13	7.8 EB05 3.6 · IC025 +1.4 3/3 methods agree	Not in label — unassessed	serious PRR 7.1	no trial data cached
Drug administration error	6	4.2 1.9–9.3ROR 4.2 · χ² 11 / p 4e-4	3.3 EB05 1.7 · IC025 +0.3	Reporting / coding artifact	serious PRR 5.4	no trial data cached
Serotonin syndrome	6	6.8 3.1–15.1ROR 6.8 · χ² 24 / p 5e-7	4.8 EB05 2.3 · IC025 +0.8 3/3 methods agree	Not in label — unassessed	serious PRR 4.5	no trial data cached

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Blindness — n=50, PRR 26.6
Fear — n=20, PRR 16.0

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Lactate?

In FDA FAERS, the most frequently co-reported reaction terms for Lactate are blindness, infusion related reaction, fear, renal injury, multi-organ failure, caesarean section. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Lactate have an FDA boxed warning?

No. The FDA label retrieved for Lactate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Lactate causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID dad7735c-709b-40ea-ab7a-15577e24a966, effective 20251029; matched on openfda.generic_name.exact:"SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 22 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.